One orange magnifying glass stands out among a group of white magnifying glasses on a pale blue background.

Table of Contents

H2 headings will appear here...

SUCCESS STATS

PBM 101

How to Evaluate PBM Performance: The Metrics, Data, and Contract Rights That Matter

How to Evaluate PBM Performance: The Metrics, Data, and Contract Rights That Matter

Portrait of SmithRx

SmithRx

Key Takeaways

  • Net pharmacy cost per member over time measures performance more reliably than discount or rebate guarantees.

  • Claims-level data, defined reports, and audit rights determine whether reported results can be verified.

  • Clinical execution, service metrics, and equal-terms renewal bids complete an employer's pharmacy scorecard.

Think back to a past pharmacy benefits renewal cycle. Your pharmacy benefit manager (PBM) reported that it met every discount and rebate guarantee, but your pharmacy spend still rose. Your benefits team had to explain that gap to finance and decide whether to renew, renegotiate, or issue a request for proposal (RFP).

That's hard to do when the PBM's own scorecard is the only one in the room. A stronger evaluation runs on your scorecard: net cost you can verify first, then clinical and service execution, then a test against the market at renewal, on equal terms.

What to Measure When You Evaluate PBM Performance

To evaluate PBM performance, measure the total net cost of the pharmacy benefit over time and confirm you can verify that cost with claims-level data. Then assess how well the PBM executes clinical programs, serves members, and partners with your benefits team.

Each area of your scorecard should answer a different question about the PBM:

  • Net cost shows what the plan paid per member after fees, rebates, and savings, and how that figure is trending.

  • Verifiability shows whether your data rights, reports, and audit scope let you confirm the PBM's numbers independently.

  • Clinical and utilization management execution shows whether members use clinically appropriate, lower-net-cost drugs.

  • Service shows how well the PBM supports members and your benefits team day to day.

A scorecard built on all four gives you a defensible basis for renewal and RFP decisions and a documented record of fiduciary oversight.

Why Discount and Rebate Guarantees Do Not Always Prove Performance

Guarantees are often the headline metric in a PBM's annual review, and they are the easiest to misread.

Network discount guarantees are typically measured as average discounts off average wholesale price (AWP). The PBM defines the claim categories behind each average, such as channel, brand or generic status, and days supply. How the PBM classifies claims into those categories can determine whether a guarantee is met.

Rebate guarantees depend on definitions too. A per-brand-claim rebate guarantee rests on assumptions about utilization, and contract definitions can change which claims count toward it. Reviewing how discount and rebate guarantees are constructed in your contract shows which definitions to test.

Drug mix is an even bigger blind spot. A PBM can lift its discount and rebate guarantee results by using more guarantee-rich products, medications with a greater-than-average pharmacy network discount or rebate payment. Total plan cost can rise even as those guarantee results improve.

The gap between cost-based and discount-based evaluation is easiest to see in an oversimplified analogy. Picture two gallons of milk. One lists at $12 and sells at 50% off for $6, while the other costs $5 with no discount, $1 less.

Drugs work the same way: a brand-name drug with a large discount off an inflated list price can still cost the plan more than a lower-net-cost alternative with a smaller discount or none. Guarantees also say nothing about how the PBM is compensated on each claim, including whether it uses spread pricing.

Meeting PBM performance guarantees shows the PBM delivered on those specific commitments. Net cost shows whether your plan got good value.

Use Net PMPM as the Primary Scorecard Metric

Per member per month (PMPM) cost is total pharmacy cost divided by the number of members and the number of months in the period. For PBM evaluation, use net PMPM, which reflects what the plan paid once fees, rebates, and savings are counted.

Ask your PBM to break net PMPM into four components: gross plan pay, administrative fees, cost-containment savings, and rebates. Seeing each component separately tells you whether a change came from drug spend, fees, savings programs, or rebate flow. A single blended number hides those movements.

Track the trend over multiple periods and segment it by generic, brand, and specialty drugs. Then identify the top plan-pay drivers by therapeutic class and by drug. Compare your figures against an external benchmark only when its definitions, population, and period match your plan's. No single external benchmark fits every plan, so set a baseline from your own net PMPM history and judge the PBM against that trend.

Use these metrics, and the questions to ask your PBM about each, to see what moves net PMPM.

Metric

What It Reveals

Question to Ask Your PBM

Net PMPM trend

Whether plan cost per member is rising or falling after fees, rebates, and savings

What changed in each net PMPM component since the last period?

Specialty share of spend

How much plan cost concentrates in high-cost therapies

Which specialty drugs drove the change, and how are they managed?

Generic dispense rate (GDR)

Whether members fill a generic when one is available

Which brand-name drugs are still dispensed when a generic is available, and why?

Biosimilar switch rate

Whether members move to a clinically appropriate biosimilar when one is available

Which brand-name biologics are still dispensed when a biosimilar is available, and why?

Top plan-pay drivers

Which drugs and therapeutic classes account for the most plan spend

For each top-spend drug, what clinically appropriate lower-cost alternatives, pharmacy channels, or savings programs could reduce plan spend?

Realized savings by program

Which cost-containment programs produced measurable savings

How do you calculate realized savings for each program?

Net PMPM trend also gives finance useful context for budget planning. With its components visible, finance can see why cost moved, and the benefits team can focus plan design changes or PBM conversations on what is driving it.

Confirm You Can Verify the Numbers

A scorecard is only as reliable as the data behind it. Verification depends on data rights, defined reports, and audit scope, and each one needs to be written into the PBM contract.

Employers that negotiate these rights before signing avoid relying on the PBM's summaries at renewal. The two areas below define what to secure.

Claims-Level Data Access

Claims-level data is where PBM transparency becomes testable, because it lets an employer check the PBM's reports and model plan design changes independently. Request each claim's ingredient cost, dispensing fee, administrative fee, plan pay, member cost share, and rebate attribution. The contract should set the delivery schedule, require a format your analysts or consultant can use, and state that the data comes without added fees.

Many employers get the summary without the detail. In the National Alliance of Healthcare Purchaser Coalitions' 2026 employer survey, 84.8% of employers answering the question reported access to aggregate pharmacy data, but only 63.3% reported complete access at the claims level.

Reporting and Audit Rights

Standard reports turn raw claims into a view you can review each period. The core reports to request from your PBM are a net PMPM breakdown, rebate reporting, and top plan-pay drivers. Add claims reporting that shows plan pay, member cost share, and cost containment applied, plus realized savings by program.

Audit rights determine whether you can check those reports against the underlying transactions. Define these terms in the contract:

  • Audit scope should cover both claims and rebates, including manufacturer payments the PBM receives.

  • Audit frequency should allow regular reviews plus a review after a material change in plan performance.

  • Auditor choice should let the employer select an independent auditor without PBM approval.

  • Contract access should give the auditor the underlying pharmacy and manufacturer agreements needed to test pricing.

Federal regulation points in the same direction. The U.S. Department of Labor published a final rule on November 2, 2026. Under it, PBMs and their affiliated brokers and consultants must disclose their direct and indirect compensation to the fiduciaries of large self-insured group health plans.

The rule takes effect January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Covered plans can audit the PBM at least once a year to verify those disclosures, using an auditor they choose. The auditor gets access to claims data and the PBM's pharmacy, manufacturer, and rebate aggregator contracts.

The rule lines up with three of the audit terms above: an annual audit, auditor choice, and contract access. Its audit is limited to disclosure accuracy, though, so broader claims and rebate audit rights still belong in your contract.

The rule applies only to self-insured plans of employers averaging at least 100 employees, or self-insured plans averaging at least 100 participants. Any employer can still request similar disclosures in its RFP and contract terms to judge whether the PBM's compensation is reasonable.

Evaluate Clinical and Utilization Management Execution

Clinical performance shows up in drug mix and member access. A PBM with strong clinical execution steers utilization toward clinically appropriate, lower-net-cost options. To evaluate that execution, review three areas: the formulary, utilization management, and specialty drug management.

Start with the formulary, because it determines which drugs the plan covers and at what cost tier, and that shapes drug mix. Ask who makes formulary decisions, what clinical evidence informs them, and how the PBM weighs net cost against list price. Then check the generic dispense rate and biosimilar switch rate to see whether generics and biosimilars are used when they are clinically appropriate and available.

Next, review how the PBM uses utilization management (UM) tools such as prior authorization and step therapy. Which drugs require prior authorization depends on the pharmacy benefit plan, and review processes vary by PBM. To evaluate a PBM's prior authorization program, ask these questions:

  • Who conducts clinical review, and what criteria do they apply to each request?

  • What are the turnaround times for standard and urgent requests?

  • How are decisions, denials, and appeal options communicated to members and prescribers?

  • What escalation path exists when a request is time-sensitive or disputed?

  • How are approval rates, turnaround, and appeals reported to the employer?

Finally, review specialty drugs, because they are high-cost therapies that often require special handling. Ask how they are managed clinically, which pharmacies dispense them, and whether the PBM's ownership of pharmacies affects where specialty claims go. Because these decisions affect both plan spend and member access, ask for the results in regular reporting throughout the plan year.

Measure Service for Members and Your Benefits Team

Service quality shapes how much administrative work lands on your benefits team and how employees experience their pharmacy benefit. You can only hold a PBM to it if the PBM reports it, so ask for experience metrics that cover both your members and your account management team.

On the member side, ask for response times for inquiries and authorizations, support availability, and how quickly member requests are resolved. Satisfaction scores help only with context, such as how many members responded, when the survey ran, and which interactions it covered.

On the employer side, measure how quickly the account management team responds to and resolves account requests. Assess the quality of strategic reviews, including whether the PBM brings analysis and recommendations or only recaps data. Track how many member escalations reach HR, since each one represents time your team spends on work the PBM should absorb.

Review these metrics alongside net cost at renewal, so service carries the same weight as price.

Benchmark at Renewal and Compare Proposals on Equal Terms

Renewal is your best chance to see how your current PBM compares with the market. That comparison only works if every bidder prices the same way.

In a PBM RFP, reprice the same claims file across all bidders, and require each PBM to price on comparable, transparent terms. Weigh true net cost and total PMPM impact, and give headline discounts the same scrutiny as guarantee results.

Price is only half of the comparison. Evaluate these contract terms alongside each proposal:

  • Compensation structure, including administrative fees and any spread pricing on pharmacy claims

  • Pass-through scope, including which rebates, discounts, and manufacturer payments reach the plan

  • Data and audit rights, including claims-level access, report set, and auditor choice

  • Ownership relationships, including affiliated pharmacies that could influence where claims are dispensed

Pass-through is a contract feature, and it does not settle alignment by itself. Confirm which dollars pass through, how the PBM is compensated, and how clinical programs are executed. Evaluate fee disclosure and compensation structure separately in every bid, since a PBM can disclose fees clearly and still earn more as drug spend grows.

How SmithRx Approaches PBM Performance

A benefits leader needs to verify net cost, see why it moved, and act on what drives it. We earn a fixed PMPM administrative fee and pass through 100% of manufacturer rebates, so our compensation does not increase when medication costs rise. Plan sponsors also get access to their pharmacy benefit data, so they can run the net PMPM scorecard above on their own claims.

To act on cost drivers, SmithRx's Drug Pathways Engine evaluates claims for the clinically appropriate lowest-net-cost drug, pharmacy source, and available savings programs. We don't own pharmacies, and for certain drugs the lowest-net-cost source can be a partner channel, such as a manufacturer-direct or cost-plus pharmacy. When a pathway requires action, our clinical and member support teams guide members and coordinate next steps with providers.

The SmithRx Partner Portal, a tool provided through our PBM service, supports benefit administration, member questions, and plan-performance analysis on that same scorecard. SmithRx clients see 20%+ lower PMPM than the industry benchmark, based on 2025 results. SmithRx clients gave us an average client satisfaction (CSAT) score of 4.7 out of 5 in 2025.

The net PMPM scorecard is most useful when you can test it against your own data. We offer a complimentary repricing analysis that compares costs, and you can contact our team to request one.

Frequently Asked Questions

How often should employers review PBM performance?

Employers should review PBM reporting on a regular schedule throughout the plan year and run a formal benchmark before each renewal. We recommend starting an RFP at least 10 to 12 months before your contract expires to allow time to compare proposals on equal terms.

What is the difference between a PBM audit and a PBM performance review?

A PBM audit generally tests whether claims, payments, and rebates match the contract, while a performance review judges net cost trend, clinical execution, and service. Employers need both because a PBM can comply with its contract while plan cost still rises.

What should employers do if their PBM will not provide claims-level data?

Treat the refusal as a performance finding and require complete claims-level data, on a set schedule and without added fees, in your next contract. Without that data, you cannot independently verify the PBM's reports.

Who should be involved in evaluating a PBM?

Benefits leaders, finance, and a benefits broker or consultant should lead the evaluation, with clinical input from a pharmacist for formulary and UM review. Finance translates net cost into budget impact, and the broker or consultant can normalize proposals at renewal.

Build this scorecard into your next PBM review, and carry the same data, reporting, and audit requirements into your renewal terms.

Ask AI about this article

Portrait of SmithRx
SmithRx

SmithRx is the #1 Modern PBM, relentlessly focused on eliminating the conflicts and complexity of legacy pharmacy benefits. Built on radical transparency and fiduciary alignment, we empower employers to take control of their pharmacy spend and experience with our 100% pass-through model.